Read by QxMD icon Read

Retinal occlusion

João Coelho, Bernardete Pessoa, Angelina Meireles
Introduction: Macular edema after central retinal vein occlusion is a common cause of vision loss. Upregulation of vascular endothelial growth factor and higher levels of inflammatory mediators have been involved in the pathogeny of the macular edema in central retinal vein occlusion. Case report: The authors report a case with non-ischemic central retinal vein occlusion that was successfully treated with a single sustained-release fluocinolone acetonide intravitreal implant...
January 2019: Therapeutic advances in ophthalmology
Yali Qin, Meiqi Ji, Tingting Deng, Dan Luo, Yingxin Zi, Lin Pan, Zhijun Wang, Ming Jin
Retinal hypoperfusion injury is the pathophysiologic basis of ocular ischemic syndrome (OIS) which often leads to severe visual loss. In this study, we aimed to establish a rat model of retinal chronic hypoperfusion by bilateral common carotid artery occlusion (BCCAO) and observe changes in the retinal function and morphology. We found that model rats showed retinal arteriosclerosis, slight dilated retinal vein, small hemangiomas, hemorrhages, vascular segmental filling, and nonperfused areas after 2 weeks of BCCAO...
January 14, 2019: Scientific Reports
Fusheng Tang, Xiuhong Qin, Jianmin Lu, Peng Song, Mingshu Li, Xiang Ma
PURPOSE: To identify the spectral domain optical coherence tomography predictors of visual prognosis in retinal vein occlusion macular edema after intravitreal conbercept injection. METHODS: Retrospective cohort study of 63 treatment-naive retinal vein occlusion macular edema eyes received pro re nata intravitreal conbercept with at least 3 months of follow-up. The best-corrected visual acuity (BCVA) and optical coherence tomography scans were recorded at baseline, 1 month, and 3 months after starting therapy...
January 10, 2019: Retina
Yosuke Takeuchi, Keiichi Nakahara, Makoto Nakajima, Yasuteru Inoue, Riyo Matsumura, Munekage Yamaguchi, Hidetaka Katabuchi, Yukio Ando
A 23-year-woman was presented for sudden-onset monocular blindness. Branch retinal artery occlusion in the right eye and multiple brain embolism were detected. Trousseau syndrome due to bilateral ovarian cancer was diagnosed; no embolic events were observed after anticoagulant therapy and surgical resection.
January 8, 2019: Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association
V A Patel, M Dunklebarger, T T Zacharia, H Isildak
Susac syndrome, a rare autoimmune disorder first described as a classic triad (encephalopathy, branch retinal artery occlusion, and sensorineural hearing loss) in 1979 by renowned physician John O. Susac, has been an advancing area of clinical interest and scientific research over the last several decades. This comprehensive review aims to succinctly highlight the breadth and detail of this enigmatic disease, with a primary focus on otologic manifestations. Topics discussed include epidemiology, pathophysiology, clinical manifestations, differential diagnoses, classification schema, laboratory investigations, characteristic audiometric findings, high-yield radiographic imaging, temporal bone histopathology, treatment strategies and overall prognosis...
December 2018: Acta Otorhinolaryngologica Italica
W Lloyd Clark, Mimi Liu, John Kitchens, Pin-Wen Wang, Zdenka Haskova
BACKGROUND: To identify baseline patient characteristics associated with early clinically significant visual acuity (VA) improvements within 3 months of treatment initiation in ranibizumab-treated patients with retinal vein occlusion (RVO) in the SHORE study. METHODS: Post hoc analysis of baseline patient characteristics in the randomized, open-label, vision examiner-masked SHORE phase 4 study that compared monthly versus pro re nata dosing of ranibizumab in patients with branch and central RVO...
January 8, 2019: BMC Ophthalmology
Lixiong Gao, Lijun Zhou, Chunyu Tian, Na Li, Weiyang Shao, Xiujun Peng, Qian Shi
BACKGROUND: Retinal vein occlusion (RVO) is a common retinal venous disorder that causes vision loss. No specific therapy has been developed. Controversy exists regarding two treatments: intravitreal dexamethasone implants and anti-vascular endothelial growth factor (VEGF). The goal of this study is to compare the effectiveness and safety of dexamethasone implants and anti-VEGF treatment for RVO. METHODS: The PubMed, Embase, and Cochrane Library databases were searched for studies comparing dexamethasone implants with anti-VEGF in patients with RVO...
January 8, 2019: BMC Ophthalmology
Matthew R Starr, Alaina L Softing Hataye, Sophie J Bakri
PURPOSE: To describe a unique presentation of multifocal paracentral acute middle maculopathy in a young patient with juvenile dermatomyositis including optical coherence tomography angiography findings. METHODS: Retrospective single case report. PATIENT: Seventeen-year-old male patient with a history of juvenile dermatomyositis presented for routine hydroxychloroquine screening. RESULTS: Optical coherence tomography revealed undulations of the outer retinal layers and retinal thinning near the fovea in both eyes...
January 3, 2019: Retinal Cases & Brief Reports
Sohan Singh Hayreh
No abstract text is available yet for this article.
February 2019: Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association
Javier Zarranz-Ventura, Anna Sala-Puigdollers, Daniel Velazquez-Villoria, Marc Figueras-Roca, Sergio Copete, Laura Distefano, Anna Boixadera, Jose García-Arumi, Alfredo Adan
PURPOSE: To evaluate the long-term cumulative probability of intraocular pressure (IOP) elevation with the intravitreal dexamethasone implant (IDI) when used to treat different indications: diabetic macular edema, uveitis, retinal vein occlusion. METHODS: 705 IDI injections (429 eyes) were assessed and Kaplan-Meier graphs were generated to assess: the probability of different levels of IOP elevation (IOP≥21, ≥25 or ≥35 mmHg), IOP change ≥10 mmHg, initiation of IOP-lowering treatment, glaucoma surgery, IOP change with repeat injections and IOP elevation in eyes with glaucoma and ocular hypertension (OHT)...
2019: PloS One
Jae Hyung Lee, Jae Yong Park, Jae Suk Kim, Je Hyung Hwang
BACKGROUND: This study aims to report a case of rapid progression of cataract to mature stage after intravitreal dexamethasone implantation for macular edema due to branch retinal vein occlusion. CASE PRESENTATION: A 59-year-old Korean male with complaints of sudden metamorphopsia and reduced visual acuity for three days in the left eye was referred to our clinic. Ophthalmological investigations included fundus photography, fluorescein angiography, and optical coherence tomography...
January 3, 2019: BMC Ophthalmology
Hyeong Min Kim, Young Joo Park, Kyu Hyung Park, Se Joon Woo
OBJECTIVES: To investigate the characteristics and temporal changes in visual field defects (VFDs) in eyes with acute central retinal artery occlusion (CRAO). DESIGN: Retrospective, observational case series. METHODS: A total of 119 patients diagnosed with acute non-arteritic CRAO through examination with Goldmann perimetry were included among the patients who visited Seoul National University Bundang Hospital between January 2009 and December 2016...
2019: PloS One
Gae-Eil Jang, Hyun-Sook Kim
No abstract text is available yet for this article.
December 28, 2018: Korean Journal of Internal Medicine
M Sampo, S Nadeau, D Denis, F Matonti
No abstract text is available yet for this article.
December 26, 2018: Journal Français D'ophtalmologie
Tianwei Qian, Mengya Zhao, Yongjing Wan, MengXiao Li, Xun Xu
OBJECTIVES: To evaluate the efficacy and safety of anti-vascular endothelial growth factor (VEGF) agents and corticosteroids for the treatment of macular oedema (ME) secondary to central retinal vein occlusion (CRVO). DESIGN: Systematic review and network meta-analysis. PARTICIPANTS: Patients from previously reported randomised controlled trials (RCTs) comparing anti-VEGF and corticosteroids for the treatment of ME secondary to CRVO. METHODS: Literature searches were conducted using PubMed, Medline, Embase, Cochrane Library and clinicaltrials...
December 28, 2018: BMJ Open
Michael S Ip, Neal L Oden, Ingrid U Scott, Paul C VanVeldhuisen, Barbara A Blodi, Thomas Ghuman, Carl W Baker
Importance: Information is needed to assess switching treatment in eyes with a poor response to 6 months of monthly administration of aflibercept or bevacizumab for macular edema from central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO). Objective: To investigate visual acuity letter score (VALS) and central subfield thickness (CST) changes from month 6 to 12 among eyes with a poor response at month 6 to monthly dosing of aflibercept or bevacizumab in the Study of Comparative Treatments for Retinal Vein Occlusion 2...
December 27, 2018: JAMA Ophthalmology
Panayiotis Christodoulou, Ioannis Katsimpris
No abstract text is available yet for this article.
2018: International Journal of Ophthalmology
Michael E Christiansen, Cumara B O'Carroll, Gyanendra Kumar, Brandon T Larsen, Oana M Dumitrascu
INTRODUCTION: Takayasu arteritis is a large-vessel vasculitis that may cause oculo-cerebral ischemia. We report a patient with visual loss as initial manifestation, and discuss transcranial Doppler (TCD) findings before and after surgical revascularization. CASE DESCRIPTION: A 19-year-old female developed episodes of transient positional right vision loss, progressing to permanent right vision loss and bright light-induced left amaurosis. Examination demonstrated subclavian bruits, palpable epigastrium aortic pulsation, faint radial pulses, right retinal pallor, arteriolar narrowing, and bilateral boxcarring...
January 2019: Neurologist
Adnan Tufail, Sue Lightman, Ahmed Kamal, Uwe Pleyer, Nuria María Gajate Paniagua, Corrine Dot, Xiao-Yan Li, Jenny Jiao, Jean Lou, Yehia Hashad
Purpose: To evaluate the long-term safety of dexamethasone intravitreal implant (DEX) in patients treated for macular edema associated with retinal vein occlusion (RVO) or noninfectious posterior segment uveitis (NIPSU) in clinical practice. Patients and methods: Multicenter (102 sites in France, Germany, Spain, UK), prospective, observational, post-authorization safety study in adult patients treated with DEX. Data collected up to 2 years after enrollment included serious adverse events (SAEs) and adverse events of special interest (AESIs; adverse drug reactions that are considered important risks associated with DEX and listed in the European Union Ozurdex Risk Management Plan)...
2018: Clinical Ophthalmology
George G Bastakis, Anastasios Stavrakakis, Avgoustinakis Nikolaos, Dimitris Dimopoulos, George Pappas
We present a case of acute endophthalmitis after intravitreal dexamethasone implant injection and discuss the management of this rare and challenging case in which the implant could not be removed. A 50-year-old woman with a history of branch retinal vein occlusion in the right eye was treated with intravitreal dexamethasone implant injection for macular oedema. Four days after injection, the patient was admitted to the department with acute pain, decreased vision, and redness. A diagnosis of acute post-intravitreal injection endophthalmitis was made...
2018: Case Reports in Ophthalmological Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"